Denosumab
Established medicineAlso known as Aukelso, Bildyos, Bilprevda, Bomyntra+14 more
Aukelso, Bildyos, Bilprevda, Bomyntra, Boncresa, Bosaya, Conexxence, Enoby, Jubbonti, Osenvelt, Ospomyv, Oziltus, Prolia, Stoboclo, Wyost, Xbryk, Xgeva, Xtrenbo.
Recent clinical, regulatory, research and industry developments relating to this drug.
CHMP positive opinion: Denosumab Ascend (EMA)
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Prevention of skeletal related events and treatment of giant cell tumour of bone
Evidence ↗Indication: Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women Kefdensis significantly reduces the risk of vertebral,… Show full indicationShow less
Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women Kefdensis significantly reduces the risk of vertebral, non-vertebral and hip fractures.Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures (see section 5.1). In men with prostate cancer receiving hormone ablation, Kefdensis significantly reduces the risk of vertebral fractures.Treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture (see section 5.1).
Indication: Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving… Show full indicationShow less
Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone.Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity.
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Journals, researchers & institutions
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology1
- Costa L1
- Dansey R1
- Goldwasser F1
- Henry DH1
- Hirsh V1
- Hungria V1
- Jiang Q1
- Jun S1
- Joan Karnell Cancer Center1
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 3 of the same disease areas as Denosumab in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- Europe PMC — research literature
- Regulatory event sources are credited in the Regulatory Timeline above.